SCHEMBL3395173

SCHEMBL3395173

Nc1nc(Cl)c2nc(Br)n(Cc3ccc(Cl)c(Cl)c3)c2n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRAP1 Q12931 7/20 0.58
HSP90B1 P14625 5/20 0.58
KMT2A Q03164 2/20 0.45
HSP90AA1 P07900 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
JAK2 O60674 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
HKDC1 Q2TB90 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KDR P35968 1/20 0.43
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
TYMS P04818 1/20 0.41
CCR2 P41597 4/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10508294 0.81 TYMS (0.56) TRAP1HSP90B1KMT2ASMN1; SMN2NPC1
SCHEMBL3389693 0.75 HDAC6 (0.63) TRAP1HSP90B1HSP90AA1HDAC6HDAC4
SCHEMBL21977308 0.72 ADORA2A (0.51) TRAP1HSP90B1KMT2ASMN1; SMN2HTT
SCHEMBL7206049 0.71 ADORA2A (0.68) ADORA2AADORA1MAPK1
SCHEMBL3423730 0.71 HDAC6 (0.62) TRAP1HSP90B1HSP90AA1KDRHDAC6
SCHEMBL3395967 0.71 HSP90AA1 (0.66) TRAP1HSP90B1HSP90AA1
SCHEMBL3394461 0.70 TRAP1 (0.67) TRAP1HSP90B1HSP90AA1ADORA2AADORA1
SCHEMBL3397111 0.67 HSP90AA1 (0.59) TRAP1HSP90B1HSP90AA1
SCHEMBL18989517 0.67 SMN1; SMN2 (0.52) KMT2ASMN1; SMN2NPC1JAK2HTT
SCHEMBL10506664 0.67 PNP (0.60) ADORA2AADORA1TYMS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2145888-A1 Deazapurine derivatives as HSP90-Inhibitors Conforma Therapeutics Corporation (US) 2010-01-20 EP disclosed
US-20070185064-A1 2-Aminopurine Analogs Having HSP90-Inhibiting Activity CONFORMA THERAPEUTICS CORPORATION (US) 2007-08-09 US disclosed
US-7138401-B2 2-aminopurine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION (US) 2006-11-21 US disclosed
EP-1670802-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS Conforma Therapeutic Corporation (US) 2006-06-21 EP disclosed
US-20050113340-A1 2-Aminopurine analogs having HSP90-inhibiting activity CONFORMA THERAPEUTICS CORPORATION 2005-05-26 US disclosed
WO-2005028434-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS CONFORMA THERAPEUTICS CORPORATION (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113340-A1 2-Aminopurine analogs having HSP90-inhibiting activity HSP90AB2P, HSP90AB1, HSP90AA1 TRAP1 22/4885HSP90B1 4/4885KMT2A 2392/4885
US-20070185064-A1 2-Aminopurine Analogs Having HSP90-Inhibiting Activity HSP90AB2P, HSP90AB1, HSP90AA1 TRAP1 22/4885HSP90B1 4/4885KMT2A 2392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.